Atlas Trials

Recurrent Bladder Cancer

26 clinical trials · Condition

Sort:Newest firstOldest first

◉ Watch Recurrent Bladder Cancer

RecordFirmDate
A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer (NCT04917809)Memorial Sloan Kettering Cancer Center2022-02-17
Afatinib in Advanced Refractory Urothelial Cancer (NCT02122172)University of Chicago2017-09-13
Urinary Diversion During Robotic Assisted Radical Cystectomy in Patients With Bladder Cancer (NCT02252393)Case Comprehensive Cancer Center2015-10-01
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers (NCT01846520)City of Hope Medical Center2013-10-01
Gemcitabine Hydrochloride and Cisplatin or High-Dose Methotrexate, Vinblastine, Doxorubicin Hydrochloride, and Cisplatin in Treating Patients With Urothelial Cancer (NCT01639521)University of Southern California2013-05-01
Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder (NCT01382706)University of Southern California2011-06-13
Broccoli Sprout Extract in Treating Patients With Transitional Cell Bladder Cancer Undergoing Surgery (NCT01108003)Roswell Park Cancer Institute2010-04-01
Pazopanib in Treating Patients With Metastatic Urothelial Cancer (NCT00471536)National Cancer Institute (NCI)2008-08-01
Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function (NCT00478361)M.D. Anderson Cancer Center2007-04-01
In the Prediction of Recurrence and Progression of NMIBC; EORTC or CUETO or Both? (NCT03174912)Ankara Training and Research Hospital2007-01-01
VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium (NCT00407485)National Cancer Institute (NCI)2006-11-01
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium (NCT00112905)National Cancer Institute (NCI)2005-10-01
Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract (NCT00112671)National Cancer Institute (NCI)2005-04-01
Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma (NCT01828736)Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie2004-02-09
Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma (NCT00072150)National Cancer Institute (NCI)2003-10-01
Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic Cancer of the Urothelium (NCT00004856)National Cancer Institute (NCI)2002-07-01
Decitabine in Treating Patients With Advanced Solid Tumors (NCT00030615)National Cancer Institute (NCI)2001-12-01
Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction (NCT00030498)National Cancer Institute (NCI)2001-12-01
Celecoxib in Treating Patients With Bladder Cancer (NCT00006124)National Cancer Institute (NCI)2000-06-01
Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer (NCT00005831)National Cancer Institute (NCI)2000-03-01
Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu (NCT00004074)National Cancer Institute (NCI)1999-08-01
Gene Therapy in Treating Patients With Advanced Bladder Cancer (NCT00003167)National Cancer Institute (NCI)1998-05-01
An Expanded Access Study of Bemarituzumab (FPA144) for a Single Patient With Recurrent Bladder Cancer (NCT03801278)Five Prime Therapeutics, Inc.

Track Recurrent Bladder Cancer automatically

Every clearance here is in the API, with alerts when new ones post.